Bruix et al. analyzed two phase III trials concerning prognostic factors and identified several predictors of first-line sorafenib OS, including macrovascular invasion, AFP levels, neutrophil-to-leukocyte ratio (NLR), extrahepatic spread, and hepatitis C [46]. The gene discussed is AFP; the disease is hepatitis C virus infection.